Phaseline

Companies › Degron Therapeutics

Degron Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DEG6498
molecular glue inducing HuR (human antigen R) degradation
ELAVL1Phase 1Malignant NeoplasmsDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07244835DEG6498Phase 1Malignant NeoplasmsOncologyDec 2028

Targets

ELAVL1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.